Status:
NOT_YET_RECRUITING
SALT for Patients With Hepatic Cirrhosis
Lead Sponsor:
RenJi Hospital
Conditions:
Liver Cirrhosis
Liver
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Hepatitis B virus (HBV) infection is a very difficult public health problem in the world. Patients often experience the trilogy of "hepatitis-cirrhosis-liver cancer". Patients with decompensated cirrh...
Eligibility Criteria
Inclusion
- ①Age 18-75 years old;
- Have a history of hepatitis B infection;
- The imaging results are consistent with the manifestations of liver cirrhosis;
- One of the following conditions: Meld score 15-40 points, esophageal and gastric variceal bleeding, refractory ascites, recurrent hepatic encephalopathy, hepatorenal syndrome, or hepatopulmonary syndrome; ⑤PS score 0-1 points; ⑥Sign the informed consent form.
Exclusion
- ①Severe thrombosis or cavernous degeneration in the portal vein system, and liver transplantation is contraindicated upon evaluation;
- Hepatic encephalopathy stage IV;
- Pulmonary arterial hypertension (moderate to high risk, WHO grade III-IV) that does not improve after medical treatment or is assessed to have contraindications for surgery; ④Special types of anatomical variations;
- Inability to tolerate surgical anesthesia (such as severe infection, cardiopulmonary insufficiency, cerebrovascular disease, etc.); ⑥Severe mental illness; ⑦Other reasons that the researcher believes are not suitable for participation.
Key Trial Info
Start Date :
December 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 30 2027
Estimated Enrollment :
47 Patients enrolled
Trial Details
Trial ID
NCT06153914
Start Date
December 1 2023
End Date
March 30 2027
Last Update
December 1 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.